Previous 10 | Next 10 |
Ingevity Corporation (NYSE:NGVT) today announced an extension of the distributorship with TRiiSO LLC (TRiiSO) to expand the distribution footprint for the company’s Capa® products from the current western United States (U.S.) to include all the U.S. and Canada. The new agreement will ...
2023-11-04 17:33:05 ET Ingevity Corporation (NGVT) Q3 2023 Earnings Conference Call November 02, 2023, 10:00 ET Company Participants John Nypaver - VP of IR & Treasurer John Fortson - President, CEO & Director Mary Hall - EVP & CFO Richard White -...
2023-11-01 16:48:22 ET More on Ingevity Ingevity Corporation: The Risk To Reward Is Currently Favorable Ingevity Corporation 2023 Q2 - Results - Earnings Call Presentation Ingevity Corporation (NGVT) Q2 2023 Earnings Call Transcript Ingevity downgraded to Hol...
HIGHLIGHT S : (comparisons versus prior year period) Net sales of $446.0 million, down 7%, compared to a record prior year Net income of $25.2 million and diluted earnings per share (EPS) of $0.69; adjusted earnings of $44.2 million and diluted adjusted EPS of $1.21 Adjusted E...
Company taking next steps in executing strategy that focuses on higher margin and higher growth specialty products, diversifies feedstocks and optimizes manufacturing network Exiting certain commodity-oriented markets that are primarily rosin-based Reducing exposure to structurally more e...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Ingevity Corporation (NGVT) is expected to report $1.22 for Q3 2023
Ingevity Corporation (NYSE:NGVT) announced today that it will release its third-quarter 2023 earnings after the stock market close on Wednesday, November 1, 2023. The company will host a live webcast on Thursday, November 2, at 10:00 a.m. (Eastern) to discuss third-quarter 2023 fiscal results...
2023-10-06 13:56:58 ET Summary Ingevity Corporation has seen declines in price due to recent earnings and balance sheet risks. Despite the leveraged balance sheet, Ingevity's diversification strategy and undervaluation make it a favorable investment. Analysts rate Ingevity as ...
2023-10-03 07:50:39 ET More on Ingevity Ingevity Corporation 2023 Q2 - Results - Earnings Call Presentation Ingevity Corporation (NGVT) Q2 2023 Earnings Call Transcript Ingevity Corporation: Headwinds Are Temporary Ingevity inks 85 MW solar power purchase dea...
News, Short Squeeze, Breakout and More Instantly...
HIGHLIGHT S : (comparisons versus prior year period) Net sales of $340.1 million, down 13% primarily as a result of the repositioning of Performance Chemicals Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adjust...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist a...